Home / Virus / SCYNEXIS spikes 8% on reports of deadly fungal infection in U.S. that could be treated with lead product candidate SCY-078 – SCYNEXIS, Inc. (NASDAQ:SCYX)
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

SCYNEXIS spikes 8% on reports of deadly fungal infection in U.S. that could be treated with lead product candidate SCY-078 – SCYNEXIS, Inc. (NASDAQ:SCYX)

As it stated in  Worms found in a package of fish at Fresno Costco  Breastfeeding moms meet downtown for  Oroville Dam spillway devastation, ruined hillside, clogged river revealed after water flow is  Fly over the newly branded water  Take a 40-second tour of bursting flowers around Sacramento  New  QB Brian Hoyer: ‘I have a lot of confidence in myself’ SUV crashes through Sacramento County Main Jail  Lessons learned from the ‘Yucks’ help Lynch pursue winning culture for GM John Lynch speaks at presser

according to

Deadly fungal infection reported in U.S.

Previously: SCYNEXIS’ IV SCY-078 on clinical hold pending investigation of adverse events in early-stage study; shares down 31% after hours (March 2)
This particular C. auris infection is systemic and is easily spread in healthcare settings.
SCYNEXIS’ lead product candidate is SCY-078, an inhibitor of an enzyme called glucan synthase, that is active against multi-drug-resistant pathogens, including those resistant to echinocandins, a class of antifungal drugs.
Some strains are resistant to all three major classes of antifungal drugs.
Nano cap SCYNEXIS (SCYX +7.6% ) perks up on the news that over 30 Americans have been diagnosed with a highly drug-resistant fungal infection caused by a yeast strain called Candida auris.

This content may collect you by Lily Jack

To follow all the new news about Viruses

Check Also

Canadian family tested for HIV after catheter found in ice cream tub; Australian kids pricked at supermarket

Workers conducted studies that got Truvada on the market for HIV prevention, and they’ve also …